TEL AVIV, Israel, June 27, 2017 /PRNewswire/ -- Therapix
Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical-stage pharmaceutical company specializing in the development
of cannabinoid-based drugs, today announced that the Company will ring The Nasdaq Stock Market Opening Bell in New York, NY on Wednesday, June 28, 2017 in honor of its initial public
offering (IPO) of American Depository Shares (ADSs) listed on the Nasdaq Capital Market in March
2017.
Dr. Elran Haber, Ph.D., Chief Executive Officer of Therapix, stated, "We're proud to celebrate the successful uplisting to the
Nasdaq Capital Market as Therapix builds recognition in the U.S. markets to grow exposure to a broader and more diverse investor
audience. As we ring the opening bell, I would also like to take this moment to acknowledge and thank the employees, investors
and partners who have supported Therapix in our journey thus far. With Therapix running two U.S. clinical studies in 2017 and
data on one of them to be released this year, today's celebration comes at a landmark point in our timeline."
A live webcast of The Nasdaq Stock Market Opening Bell ceremony will be available at https://livestream.com/nasdaq/live and also on the
Investor Relations portion of
Therapix's website at www.therapixbio.com.
Therapix began trading on the Nasdaq Capital Market on March 22, 2017, under the symbol
"TRPX".
About Therapix Biosciences
Therapix Biosciences Ltd. (Nasdaq: TRPX) is a specialty clinical-stage pharmaceutical company focused on developing
technologies and therapeutics based on cannabinoid pharmaceuticals. The Company's clinical pipeline assets follow a de-risked
505(b)(2) regulatory pathway benefitting from Therapix's unique proprietary formulations based on repurposing an FDA approved
synthetic cannabinoid (dronabinol). Therapix's lead compound, THX-TS01, is currently in Phase 2 clinical trials for Tourette's
Syndrome and the Company intends to initiate a Phase 1 clinical study of THX-ULD01 for the treatment of Mild Cognitive
Impairment, for which no FDA-approved therapies currently exist. Please visit our website for more information at www.therapixbio.com.
Contacts
Josh Blacher
Chief Financial Officer
josh@therapixbio.com
Tirth Patel (investors)
Edison Group
tpatel@edisongroup.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/therapix-biosciences-to-ring-the-nasdaq-stock-market-opening-bell-on-june-28-300480633.html
SOURCE Therapix Biosciences Ltd